revers
transcriptas
inhibitor
rti
includ
nucleosid
rti
nrti
nonnucleosid
rti
nnrti
critic
antiretrovir
drug
treatment
human
immunodefici
viru
hiv
infect
emerg
multirti
resist
call
develop
potent
therapeut
regimen
rtiresist
strain
demonstr
combin
azidothymidin
azt
new
nnrti
develop
diarylpyridin
dapa
diarylanilin
daan
result
strong
synerg
infect
diverg
strain
includ
resist
nrti
nnrti
suggest
potenti
develop
novel
nnrti
salvag
therapi
hivacquir
immun
defici
syndrom
aid
patient
revers
transcriptas
rt
import
target
develop
drug
hiv
human
immunodefici
viru
import
role
life
cycl
rt
inhibitor
rti
includ
varieti
nucleosid
nonnucleosid
revers
transcriptas
inhibitor
nrti
nnrti
inhibit
convers
singlestrand
viral
rna
doublestrand
provir
dna
infect
process
rti
key
compon
highli
activ
antiretrovir
therapi
haart
use
clinic
howev
rapid
emerg
multirti
resist
led
failur
patient
respond
current
haart
recent
xie
colleagu
identifi
two
class
novel
nnrti
diarylanilin
daan
diarylpyridin
dapa
see
figur
extrem
high
antihiv
efficaci
improv
resist
profil
studi
combin
new
dapa
daannnrti
ie
azidothymidin
azt
explor
potenti
synergist
antivir
effect
laboratoryadapt
primari
well
rtiresist
strain
meanwhil
nnrti
drug
nevirapin
nvp
etravirin
etr
use
control
synergi
nvp
etravirin
etr
use
control
synergi
azt
nvp
azt
etr
previous
report
herein
report
synergist
result
new
dapa
daannnrtisazt
combin
shown
tabl
nnrtiazt
combin
exhibit
synergist
effect
infect
laboratoryadapt
strain
iiib
subtyp
bal
subtyp
primari
isol
subtyp
subtyp
c
combin
index
ci
rang
combin
show
strongest
synerg
iiib
infect
ci
dose
reduct
azt
combin
azt
novel
nnrti
exhibit
strong
synerg
compar
combin
azt
fdaapprov
nnrti
drug
nvp
suggest
new
nnrti
potenti
use
hivacquir
immun
defici
syndrom
aid
patient
fail
respond
current
use
nnrti
subsequ
test
nnrtiazt
combin
aztresist
strain
test
alon
valu
azt
two
resist
strain
nm
respect
wherea
nnrti
test
alon
rang
nm
combin
valu
azt
two
resist
strain
rang
nm
wherea
nnrti
rang
nm
ci
see
tabl
gener
azt
combin
exhibit
stronger
synerg
two
resist
strain
combin
azt
nvp
see
tabl
exampl
ci
valu
combin
azt
new
nnrti
aztresist
strain
rang
respect
ci
valu
combin
azt
current
fdaapprov
nnrti
aztresist
strain
rang
respect
see
tabl
result
suggest
new
nnrti
may
use
treat
patient
mutant
resist
current
avail
rti
shown
tabl
nnrtiazt
combin
exhibit
synergist
effect
infect
laboratoryadapt
strain
iiib
subtyp
bal
subtyp
primari
isol
subtyp
subtyp
c
combin
index
ci
rang
combin
show
strongest
synerg
iiib
infect
ci
dose
reduct
azt
combin
azt
novel
nnrti
exhibit
strong
synerg
compar
combin
azt
fdaapprov
nnrti
drug
nvp
suggest
new
nnrti
potenti
use
hivacquir
immun
defici
syndrom
aid
patient
fail
respond
current
use
nnrti
subsequ
test
nnrtiazt
combin
aztresist
strain
test
alon
ic
valu
azt
two
resist
strain
nm
respect
wherea
nnrti
test
alon
rang
nm
combin
ic
valu
azt
two
resist
strain
rang
nm
wherea
nnrti
rang
nm
ci
see
tabl
gener
azt
combin
exhibit
stronger
synerg
two
resist
strain
combin
azt
nvp
see
tabl
exampl
ci
valu
combin
azt
new
nnrti
aztresist
strain
rang
respect
ci
valu
combin
azt
current
fdaapprov
nnrti
aztresist
strain
rang
respect
see
tabl
result
suggest
new
nnrti
may
use
treat
patient
mutant
resist
current
avail
rti
dose
reduct
fold
calcul
use
follow
formula
ic
valu
inhibitor
test
aloneth
ic
valu
inhibitor
test
combin
anoth
inhibitor
final
investig
cooper
effect
new
nnrti
combin
azt
multipl
rtiresist
strain
strain
contain
mutat
rt
amino
acid
residu
render
resist
mani
nrti
nnrti
appear
particularli
resist
nvp
azt
ic
nm
respect
test
alon
hand
strain
rel
sensit
recent
approv
nnrti
well
new
nnrti
develop
includ
rang
nm
nnrtiazt
combin
exhibit
strong
synerg
multirtiresist
strain
ci
rang
dose
reduct
rang
nnrti
azt
see
tabl
find
suggest
combin
nnrti
azt
lead
strong
synerg
infect
mutant
resist
nrti
nnrti
summari
new
nnrti
develop
possess
improv
antivir
activ
strain
particularli
resist
rti
found
combin
new
nnrti
azt
result
synerg
strong
synerg
diverg
laboratoryadapt
primari
strain
well
resist
nrti
nnrti
therefor
new
nnrti
develop
new
addit
antihiv
drug
arsen
effect
use
salvag
therapi
hivaid
patient
fail
respond
current
avail
antiretrovir
drug
antihiv
microbicid
prevent
sexual
hiv
transmiss
nevertheless
preclin
studi
vivo
efficaci
safeti
includ
long
term
toxic
nnrtinrti
combin
select
drug
mutant
warrant
order
establish
therapeut
potenti
drug
combin
clinic
applic
addit
combin
investig
nnrti
modern
prefer
nrti
tenofovir
tdftaf
ftc
also
test
futur
cell
inhibitor
azt
nvp
laboratoryadapt
strain
iiib
bal
primari
strain
aztresist
strain
rtiresist
strain
obtain
nation
institut
health
aid
research
refer
reagent
program
small
molecul
nnrti
synthes
previous
describ
inhibitori
activ
differ
drug
infect
differ
strain
test
cell
assay
previous
describ
briefli
presenc
absenc
test
inhibitor
grade
concentr
cell
express
coreceptor
infect
strain
tcid
tissu
cultur
infect
dose
fourth
day
postinfect
cultur
supernat
collect
test
antigen
elisa
previous
describ
ratio
nnrti
daan
dapa
nrti
azt
combin
determin
base
ic
concentr
inhibitor
achiev
inhibit
viral
infect
valu
test
alon
exampl
ic
valu
nnrti
azt
nrti
inhibit
iiib
infect
test
alon
nm
respect
see
tabl
ratio
azt
combin
make
concentr
nnrti
nrti
combin
equal
potenc
ratio
nnrti
azt
calcul
way
ic
ci
combin
index
valu
calcul
use
calcusyn
program
strength
synerg
indic
follow
ci
valu
strong
synerg
strong
synerg
synerg
moder
synerg
slight
synerg
summari
result
suggest
newli
identifi
nnrti
use
combin
nrti
azt
salvag
therapi
hivaid
patient
fail
respond
current
avail
antiretrovir
drug
antihiv
microbicid
prevent
sexual
hiv
transmiss
author
contribut
sj
conceiv
design
supervis
project
fy
wl
lw
yd
xl
qw
perform
experi
sj
fy
wl
lx
integr
data
wrote
paper
